IPN Ipsen SA

IPSEN - Buy-back programme - Art 5 of MAR - Week 30 - 2025

IPSEN - Buy-back programme - Art 5 of MAR - Week 30 - 2025

Aggregated presentation by day and by market









Statement of transactions in own shares from July 21st to July 25th 2025
       
Name of the issuerIdentity code of the issuer

(Legal Entity Identifier) 		Day of the transactionIdentity code of the financial instrument Total daily volume (in number of shares)Daily weighted average purchase price of the sharesMarket (MIC Code)
IPSEN549300M6SGDPB4Z94P1121/07/2025FR0010259150 350 106,16429AQEU
IPSEN549300M6SGDPB4Z94P1121/07/2025FR0010259150 1 300 106,16408CCXE
IPSEN549300M6SGDPB4Z94P1121/07/2025FR0010259150 250 106,14TQEX
IPSEN549300M6SGDPB4Z94P1121/07/2025FR0010259150 2 390 106,43301XPAR
IPSEN549300M6SGDPB4Z94P1122/07/2025FR0010259150 300 105,20AQEU
IPSEN549300M6SGDPB4Z94P1122/07/2025FR0010259150 1 000 105,20CCXE
IPSEN549300M6SGDPB4Z94P1122/07/2025FR0010259150 300 104,96667TQEX
IPSEN549300M6SGDPB4Z94P1122/07/2025FR0010259150 3 000 105,51353XPAR
IPSEN549300M6SGDPB4Z94P1123/07/2025FR0010259150 200 108,645AQEU
IPSEN549300M6SGDPB4Z94P1123/07/2025FR0010259150 300 108,06667CCXE
IPSEN549300M6SGDPB4Z94P1123/07/2025FR0010259150 200 108,00TQEX
IPSEN549300M6SGDPB4Z94P1123/07/2025FR0010259150 2 400 108,13342XPAR
IPSEN549300M6SGDPB4Z94P1124/07/2025FR0010259150 650 111,86154CCXE
IPSEN549300M6SGDPB4Z94P1124/07/2025FR0010259150 150 111,93333TQEX
IPSEN549300M6SGDPB4Z94P1124/07/2025FR0010259150 3 252 111,77211XPAR
IPSEN549300M6SGDPB4Z94P1125/07/2025FR0010259150 280 111,50821AQEU
IPSEN549300M6SGDPB4Z94P1125/07/2025FR0010259150 980 111,64612CCXE
IPSEN549300M6SGDPB4Z94P1125/07/2025FR0010259150 200 111,52TQEX
IPSEN549300M6SGDPB4Z94P1125/07/2025FR0010259150 3 143 111,67378XPAR
   TOTAL20 645 108,6488 

Attachment



EN
29/07/2025

Underlying

IPNIpsen SA

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Ipsen SA

 PRESS RELEASE
Free
IPN IPSEN SA

IPSEN - Buy-back programme - Art 5 of MAR - Week 30 - 2025

IPSEN - Buy-back programme - Art 5 of MAR - Week 30 - 2025 Aggregated presentation by day and by marketStatement of transactions in own shares from July 21st to July 25th 2025       Name of the issuerIdentity code of the issuer (Legal Entity Identifier) Day of the transactionIdentity code of the financial instrument Total daily volume (in number of shares)Daily weighted average purchase price of the sharesMarket (MIC Code) IPSEN549300M6SGDPB4Z94P1121/07/2025FR0010259150 350 106,16429AQEUIPSEN549300M6SGDPB4Z94P1121/07/2025FR0010259150 1 300 106,16408CCXEIPSEN549300M6SGDPB4Z94P1121/07/2025FR0...

13h / 58m 1 EN
 PRESS RELEASE
Free
IPN IPSEN SA

IPSEN - Achats effectués dans les conditions de l'Article 5 du Règleme...

IPSEN - Achats effectués dans les conditions de l'Article 5 du Règlement MAR - Semaine 30 - 2025 Présentation agrégée par jour et par marchéDéclaration des transactions sur actions propres réalisées du 21 juillet au 25 juillet 2025       Nom de l'émetteurCode identifiant de l'émetteur (code LEI)Jour de la transactionCode identifiant de l'instrument financierVolume total journalier (en nombre de titres)Prix pondéré moyen journalier d'acquisitionCode identifiant marchéIPSEN549300M6SGDPB4Z94P1121/07/2025FR0010259150350106,1642857AQEUIPSEN549300M6SGDPB4Z94P1121/07/2025FR00102591501300106,164076...

13h / 58m 1 EN
 PRESS RELEASE
Free
IPN IPSEN SA

Cabometyx® approved in the EU for previously treated advanced neuroend...

Cabometyx® approved in the EU for previously treated advanced neuroendocrine tumors Cabometyx® is the first and only systemic therapy to be approved in the European Union for previously treated unresectable or metastatic neuroendocrine tumors, regardless of tumor site, grade or previous non-somatostatin analogue-based systemic therapy1,2Approval based on pivotal CABINET Phase III trial which demonstrated a 77% and 62% reduction in the risk of disease progression or death versus placebo in advanced pancreatic and extra-pancreatic neuroendocrine tumors, respectively3,4 PARIS, FRANCE, 24 July...

July 24, 2025 1 EN
 PRESS RELEASE
Free
IPN IPSEN SA

Approbation de Cabometyx® dans l’UE pour les tumeurs neuroendocrines a...

Approbation de Cabometyx® dans l’UE pour les tumeurs neuroendocrines avancées précédemment traitées Cabometyx® est le premier et unique traitement systémique autorisé dans l’Union européenne pour les tumeurs neuroendocrines non résécables ou métastatiques précédemment traitées, indépendamment de la localisation de la tumeur, de sa gravité et de l’administration ou non d’un traitement systémique auparavant, autre qu’un traitement par analogue de la somatostatine1,2.Approbation basée sur l’essai pivotal de Phase III CABINET qui a démontré une réduction de 77 % et 62 % du risque de progression...

July 24, 2025 1 EN
 PRESS RELEASE
Free
IPN IPSEN SA

Ipsen announces changes to its Executive Committee

Ipsen announces changes to its Executive Committee PARIS, FRANCE, 23 July 2025 - Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty care biopharmaceutical company, today announced the following changes to its Executive Committee: Mari Scheiffele is appointed to EVP, Chief Product OfficerAndreas Gerber is appointed to EVP, Head of InternationalCaroline Sitbon is appointed to EVP, General Counsel Mari, Andreas and Caroline will report to Ipsen’s Chief Executive Officer, David Loew, beginning September 1, 2025. After 4 years successfully leading the commercial operations for the Internat...

July 23, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch